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ABSTRACT
Background. Peritoneal surface malignancies (PSMs) are
usually staged using Sugarbaker’s Peritoneal Cancer Index
(PCI) and completeness of cytoreduction score (CC-s).
Although these staging tools are essential for selecting
patients and evaluating outcome after cytoreductive sur-
gery (CRS) plus hyperthermic intraperitoneal
chemotherapy (HIPEC), both scoring models lack some
anatomic information, thus making staging laborious and
unreliable. Maintaining Sugarbaker’s original concepts, we
therefore developed a computerized digital tool, including
a new anatomic scheme for calculating PCI and CC-s
corresponding closely to patients’ real anatomy. Our new
anatomic model belongs in a web-based application known
as the PSM Staging System, which contains essential
clinical and pathological data for the various PSMs cur-
rently treated.
Methods. The new digital tool for staging PSM runs on a
personal computer or tablet and comprises male and female
colored anatomic models for the 13 endoabdominal
regions, with borders defined according to real anatomic
landmarks. A drag-and-drop tool allows users to compute
the PCI and CC-s, making it easier to localize and quantify
disease at diagnosis and throughout treatment, and residual
disease after CRS.
Conclusions. Once tested online by registered users, our
computerized application should provide a modern, shareable,
comprehensive, user-friendly PSM staging system. Its ana-
tomic features, along with the drag-and-drop tool, promise to
make it easier to compare preoperative and postoperative
PCIs, thus improving the criteria for selecting patients to
undergo CRS plus HIPEC. By specifying the size, site, and
number of residual lesions after CRS plus HIPEC, our digital
tool should help stratify patients into outcome classes.
Peritoneal spread from an intraperitoneal neoplasia, or
primary peritoneal tumors, currently identified as peri-
toneal surface malignancies (PSMs), are dismal events.
Thanks to the pioneering efforts of Sugarbaker, their
treatment has markedly improved results in the past
20 years.1,2 Standardizing procedures for surgical cytore-
duction (peritonectomy procedures) associated with
perioperative chemotherapy, combined with hyperthermia,
hyperthermic intraperitoneal chemotherapy (HIPEC) can
now guarantee hitherto unforeseeable results and quality of
life in selected cases.3–7 In all malignancies, the extent of
disease at diagnosis, and residual disease after treatment,
are assessed with specific staging classifications. Staging
systems provide the basis for defining which groups to
include in clinical trials, and are the benchmark for eval-
uating patients’ outcome after treatment. For many years
now, staging for patients with PSMs has mainly used two
classification models, both developed and perfected by
Sugarbaker.8 The first, the Peritoneal Cancer Index (PCI),
assesses the extent of peritoneal disease at diagnosis and
treatment. It quantitatively combines cancer implant size
with tumor distribution throughout 13 abdominopelvic
regions, producing a maximum score of 39. Two transverse
and two sagittal straight lines, together with small bowel
subdivision, artificially divide the abdomen into 13 regions
(Fig. 1a). The second, the completeness of cytoreduction
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score (CC-s), analyzes the completeness of cytoreduction
obtained by surgical procedures, and quantifies, from CC0
to CC3, eventual residual disease according to its size
(Fig. 1b). Patients’ PSM outcome achieved with a com-
bined treatment approach [cytoreductive surgery (CRS)
plus HIPEC] correlates inversely with the extent of disease
(PCI at diagnosis), and directly with the completeness of
cytoreduction obtained at surgery. In specific clinical
conditions, such as peritoneal metastases from colorectal
and gastric cancer, the amount of peritoneal spread nega-
tively influences the patient’s outcome to such an extent
that the PCI score seems to acquire a specific role as a cut-
off value for selecting candidates for CRS plus
HIPEC.6,9–12 In these patients, only an extremely low PCI
score and complete cytoreduction (CC0) allow long-term
survival.13,14 In less aggressive PSM (low-grade appen-
diceal pseudomyxoma and peritoneal metastases from
ovarian cancer), the major prognostic indicator seems to be
the CC-s. Even in patients who have a high PCI, CRS plus
HIPEC could achieve a good outcome provided that it
leaves minimal residual disease.3,15
The currently available PCI and CC-s classifications,
according to Sugarbaker, leave room for improvement. The
poorly informative two-dimensional anatomic model for
scoring the PCI fails to reflect the patient’s real anatomy, as
seen by the radiologist or surgeon. Although Sugarbaker
himself later listed the anatomic structures involved in the
13 abdominopelvic regions,16 the model lacked depth, the
anatomic structures contained in a specific abdominal
region overlapped, and imaginary lines subdivided the
regions. Hence, the problem remained unsolved. The PCI
applied in this way therefore tends to make assessment
more laborious and probably yields less reliable diagnostic
and surgical findings on the extent of disease. Similar
limitations apply to the CC-s because it completely lacks
an anatomic model and therefore gives no information on
the sites of residual disease or their number.
Despite keeping Sugarbaker’s original concepts, the
foregoing shortcomings prompted us to facilitate PSM
staging by optimizing the same anatomical model for
applying the PCI and CC-s. With this concept in mind, we
aimed to develop a computerized scheme containing ima-
ges with a three-dimensional effect suitable for use during
diagnosis or therapy and corresponding as closely as pos-
sible to the patient’s real anatomy. We included this model
in a new web application known as the PSM Staging
FIG. 1 a PCI and b CC-s,
according to Sugarbaker. PCI
Peritoneal cancer index, CC-s
completeness of cytoreduction
score
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System, which contains the main clinical and pathological
data for the various PSMs currently treated (www.psmss.
net). The digital technology used in the new anatomic
model should help localize and quantify, with greater
precision, the extent of peritoneal disease (PCI) in diag-
nostic and surgical settings, specifying the size and number
of lesions. Using the same anatomic model, the same
digital tool also specifies the size and number of residual
lesions after CRS, as well as the site of residual disease.
Both user-friendly features aim to make the PCI and CC-s
easier to mark and more reliable, therefore facilitating
information exchange among physicians involved in
treating PSMs. By providing a single web application for
radiologists and surgeons, we also wanted to make it easier
to compare preoperative and surgical disease staging,
thereby improving patient selection criteria. With a more
realistic anatomic model, we finally sought to extend cur-
rent prognostic information correlating the PCI and CC-s
according to the specific anatomic sites.
COMPUTERIZED PERITONEAL SURFACE
MALIGNANCY STAGING SYSTEM
Based on the classic, graphical black and white repre-
sentation for assessing the PCI in PSMs, we developed
new anatomic models for males and females, illustrating
the patient’s real anatomy in color, allowing a three-di-
mensional image effect, and maintaining, as far as
possible, Sugarbaker’s concepts, including clockwise
numbering, total number of regions, and lesion size score
criteria, thus creating a topographic scheme (Fig. 2). The
same new model, always according to Sugarbaker’s lesion
size score criteria, served to localize and quantify residual
disease and calculate the CC-s after CRS. To avoid
structural overlap, we indicated the abdominal wall as
region 0, comprising the greater omentum anatomically
overlying the abdominal organs. We defined the borders
demarcating the various endoabdominal regions unequiv-
ocally according to anatomic landmarks: falciform
ligament, gastrosplenic ligament, transverse mesocolon,
mesenteric root, iliac axes, and pelvic inlet. The concepts
used for identifying regions 9–12 (the upper and lower
jejunum and ileum) remained unchanged. We illustrated in
color the specific organs and structures contained in each
region (Fig. 3). Regions 1–3 comprised the organs and
structures between the transverse mesocolon and
diaphragmatic domes; two landmarks (the falciform liga-
ment and gastrolienal ligament) divided the regions
longitudinally. Region 1 included the upper surface of the
right liver lobe, the undersurface of the right hemidi-
aphragm, the gallbladder and hepatic pedicle, the first
duodenal portion, and right colonic flexure. Region 2
included the left lobe of the liver, anterior and posterior
surface of the stomach, transverse colon between the right
and left colonic flexure and its mesocolon, lesser omentum
and omental bursa with the anterior surface of the pan-
creas, and portion of the greater omentum between the
greater curvature of the stomach and transverse colon.
Region 3 included the undersurface of the left hemidi-
aphragm, pancreatic tail, gastrosplenic ligament, spleen,
and the left colonic flexure (Fig. 3). Regions 4 and 8 were
demarcated superiorly by the transverse mesocolon, infe-
riorly by the iliac axes, and laterally by the right and left
abdominal gutter. The two regions were divided longitu-
dinally by the mesenteric root, and both regions included
the ascending and descending colon and mesocolon;
region 4 included the fourth duodenal portion and the
Treitz ligament. Regions 5–7 lay in the space between the
iliac axes and the pelvic inlet, separated by the only
imaginary line joining the aortic bifurcation to the upper
boundary of the pelvic inlet. Region 5 included the sig-
moid colon and its mesocolon, and, in women, the left
ovary and ovarian tube. Region 7 included the cecum,
appendix, the last 10 cm of the distal ileum, and, in
women, the right ovary and ovarian tube. Region 6,
delimited by the pelvic inlet, included the intraperitoneal
rectum, the Douglas pouch, the peritoneum covering the
bladder, and, in women, the uterus. For calculating the
PCI, the scheme for each region contained three light-grey
FIG. 2 New regional
topographic scheme (male/
female) suggested for
computing PCI and CC-s. PCI
Peritoneal cancer index, CC-s
completeness of cytoreduction
score
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to black circles, differing in diameter and representing the
different lesion size scores (LS1, LS2, and LS3) that could
be dragged to the involved anatomic structure so that the
computerized system calculated the final score. Similarly,
for calculating the CC-s, each region contained three light-
grey to black circles, differing in diameter and represent-
ing the size of residual disease in a specific region (CC1,
CC2, and CC3). The PSM staging system also allowed the
user, while dragging the three circles for calculating the
PCI or CC-s, to specify, exclusively for LS1/2 and CC1/2,
FIG. 3 Organs and anatomic structures contained in each region
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the number of presurgical, perioperative, or residual
cancerous implants in each region.
WEB APPLICATION TECHNICAL
SPECIFICATIONS
The PSM staging system is a web-based application
accessible through a network that uses a standard web
browser as the user terminal and therefore runs on tradi-
tional network protocols. To ensure fully secure data
management, a data encryption protocol allows safe
communication from the source to the recipient (end-to-
end) in transfer control protocol/internet protocol (TCP/IP)
networks supplying authentication, data integrity, and full
data transport-level encryption. The PSM staging system is
written in a cross-platform language (HTML5), with the
user’s interface code specified in remote. This solution
substantially affects functioning; the major advantage is
that the web application has no influence whatsoever on
the device’s memory capacity or on its ability to calculate
data, given that the core processor and user’s interface are
on a remote server. Through their supplied password,
authenticated users, once connected to the system, will be
able to input data for new patients or update their pre-
existing data. Using a simple drag-and-drop system, the
user will be able to indicate the extent, site, and number of
malignant implants present at diagnosis and therapy, or
eventually as residual lesions after surgery, positioning
them within the anatomic model, and the system will
record all the data inserted on cloud. All data inserted can
be visualized and compared, and also exported as a PDF
document in a completely anonymous manner. No recor-
ded information will in any way be traceable back to the
patient. The system will be optimized for use on a tablet
(including iPad, Galaxy Tab, Xperia, and Nexus 9) or
computer [personal computer (PC), Apple], and updated to
run on all the latest-generation web browsers.
DISCUSSION
Our computerized, web application for staging PSM
fulfills an unmet need for a modern, shareable, compre-
hensive, user-friendly staging system for a life-threatening,
although in selected cases nowadays, treatable disease. Our
web-based system has another advantage; it collects the
main information for each patient, including clinical fea-
tures (performance status, histology, disease settings),
extent of disease at diagnosis and at surgery (PCI), and
residual disease after surgery (CC-s), and distinguishes
these features according to the various PSM origins.
The colored images with a three-dimensional effect in
our anatomic model also help to describe more accurately
the spatial extent of PSM. Having the most precise
information possible on the extent and sites involved by
malignant spread is an essential requisite for planning
therapy and assessing outcome.
Despite keeping Sugarbaker’s original concepts, subdi-
viding the various abdominal regions according to real
rather than imaginary boundaries, and describing them in
detail, as well as including the user-friendly drag-and-drop
feature, makes computing the PCI an easier task and should
provide more reliable findings. The new subdivision, dis-
tinguishing the abdominal wall apart from the other
regions, received strong support from publications, indi-
cating abdominal wall disease as being responsible for high
postoperative morbidity, and identifying it as an indepen-
dent prognostic variable.17,18 Visualizing the various
abdominal regions in detail allows the physician to far
more precisely localize malignant disease in each anatomic
site, thus defining the relationship between the organs and
structures involved and outcome, a problem so far
addressed only for the small bowel.10 In general, these
advantages could also help to overcome the reported
drawbacks in Sugarbaker’s original PCI.16,19,20 These new
features, as well as the drag-and-drop tool, should make it
easier to compare the PCI computed in the preoperative
setting from diagnostic imaging or at laparoscopy with the
PCI computed by the surgeon at surgical exploration, thus
improving the patient selection criteria. Although the main,
currently used imaging techniques [computed tomography
(CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET)/CT] achieve high reliability
indexes when undertaken by radiologists experienced in
this field, intraoperative assessment tends to disclose
malignant implants that diagnostic imaging before CRS has
missed or underestimated, especially in specific abdominal
regions.21,22 The problem on how to select patients with
PSM to undergo surgery acquires especial importance in
patients with PSM from colorectal and gastric cancer,
given the reportedly high incidence of open–close
procedures.14,23
A distinctive innovation in our PSM staging system is
that for LS1 and LS2 we explicitly specify the number of
lesions found in a given abdominal region. Although these
data leave the PCI classification unchanged, knowing the
number of lesions present in each region could provide
important, previously unavailable information that could
help guide therapy and indicate the patient’s outcome.
By using the same anatomic model and specifying the
size, site, and number of residual lesions after CRS, our
digital tool addresses the major, so far under-investigated
problem related to the completeness of cytoreduction.24–26
Despite the strict selection criteria usually applied in the
more accredited experienced centers, and regardless of the
type of PSM, minimal residual disease is a frequent event
in patients treated with CRS plus HIPEC and is directly
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proportional to the PCI.26 Even though minimal residual
disease (CC1), with the exception of PSMs from gastric
cancer,13,26 is usually considered an acceptable result after
CRS plus HIPEC, the outcome depends on several vari-
ables, including the biologic aggressiveness of the original
PSM, perfusion variables, and chemosensitivity.27,28 Given
that survival rates differ significantly between CC0 and
CC1 for PSM of gastric or colorectal origin, and differ less
in mesothelioma and pseudomyxomas,3,6,13,29 the com-
pleteness of cytoreduction is a dynamic concept. Whenever
CC0 and CC1 scores yield minor differences in survival,
our tool can supply extra, previously unavailable infor-
mation about the number and sites of residual disease, thus
stratifying patients into outcome classes, as others have
already suggested for peritoneal mesothelioma.30,31 In
patients with minimal residual disease, our digital tool can
therefore provide indications for iterative CRS plus
HIPEC,32,33 and help in planning further chemotherapy
sessions.
Among the possible limitations related to our comput-
erized PSM staging system is convincing those who are
used to applying conventional staging classifications and
concentrating their efforts on therapy to accept and use a
modern digital anatomic tool. These drawbacks will
eventually become evident as the surgical groups involved
in treating PSM begin to use our online web application.
An immediate future direction is to update our anatomic
PSM staging system according to the latest research on
integrated anatomic–biologic prognostic models.20,34,35
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